Trinayan Kashyap

Trinayan brings more than a decade of preclinical and clinical experience in oncology and inflammatory diseases to his role at hC Bioscience. Prior to joining their team, Trinayan was Executive Director of Research at Karyopharm Therapeutics, where he was a key member of the discovery effort for the first-in-class selective inhibitor of nuclear export (SINE) compound, Xpovio (selinexor). He made major contributions to the development of the Investigator’s Brochure, as well as multiple regulatory authority applications for market authorization, which ultimately led to the approval of selinexor for the treatment of multiple myeloma and diffuse large B-cell lymphoma. Trinayan also initiated the preclinical development of eltanexor, another SINE compound, which is currently being evaluated in clinical trials. In addition, Trinayan led the Karyopharm Expanded Access Program, broadening the global reach of selinexor treatment. He published a number of manuscripts based on his research efforts and numerous collaborations, and was named as inventor on two patents related to nuclear transport modulators.

Prior to Karyopharm, Trinayan studied the role of cell adhesion molecules in cancer invasion in the laboratory of Dr. Issac Rabinovitz at Harvard Medical School/Beth Israel Deaconess Medical Center.

Trinayan obtained his MS in Biology from the University of Massachusetts, Lowell and is pursuing his MBA from the Isenberg School of Management at the University of Massachusetts, Amherst.